Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001062993-25-009379
Filing Date
2025-05-14
Accepted
2025-05-14 16:33:51
Documents
1
Period of Report
2025-05-13

Document Format Files

Seq Description Document Type Size
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.html 4  
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.xml 4 3819
  Complete submission text file 0001062993-25-009379.txt   5493
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Issuer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ACHILLION PHARMACEUTICALS, INC. 300 GEORGE STREET NEW HAVEN CT 06511
Business Address
Truitt Joseph (Reporting) CIK: 0001452429 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36510 | Film No.: 25946378